Sangamo BioSciences, Inc. announced today the presentation of new data demonstrating sustained control of HIV viral load at or below the limit of detection for 14 weeks in an SB-728-T- treated HIV-infected subject who was not on antiretroviral therapy .
http://www.drugs.com/clinical_trials/sangamo-hiv-reduces-viral-load-16261.html?
http://www.drugs.com/clinical_trials/sangamo-hiv-reduces-viral-load-16261.html?
No comments:
Post a Comment